Nephros believes that identifying, recruiting and maintaining a solid management and engineering team are as important as the technology itself. Experience has often revealed the challenges in "translating" ideal clinical needs into a practical commercial product. To this end, we have assembled a team with an invaluable combination of clinical, engineering and dialysis industry backgrounds, and continue to recruit such individuals. Thus Nephros retains an unparalleled ability to balance clinical and commercial requirements, optimizing products and therapies at very early stages in the development process. With extensive experience innovating in the medical device domain, the Nephros team can ensure a constant stream of new product ideas to continually expand our product line.

Our Management and Engineering Team

Ernest A. Elgin III - President, CEO
Mr. Elgin has 20 years of career experience, including solid leadership roles within large and small organizations. He was most recently Vice President of Business Development and COO for Novaflux Technologies, Inc. Prior to joining Novaflux in September 2004, he spent four years as Vice President, Healthcare for EHC Group, a New York based consulting organization providing market and business development services for healthcare related organizations. Mr. Elgin has also held product and business development roles with Becton Dickinson, Olympus America, and E-Z-EM, Inc. Mr. Elgin started his career as a Financial Analyst with Salomon Brothers. Mr. Elgin earned his Bachelor of Arts Degree from Queens College and his MBA from Long Island University.

Gerald J. Kochanski - Chief Financial Officer

Mr. Kochanski is a Certified Public Accountant with over thirty years of experience in finance and accounting. With a strong track record in growing companies, he has played a key role in several major corporate collaborations, successfully completing public and private financial transactions. Mr. Kochanski joins the company from Lordi Consulting LLC, where he has served as Director since 2007. Prior to his tenure at Lordi, he spent three years with American Water Enterprises, Inc. as Chief Financial Officer and from 1998 through 2004 was Chief Financial Officer for Scanvec Amiable Limited. Prior to 1991, Mr. Kochanski demonstrated his financial and management leadership at Gist-Brocades Food Ingredients, Inc., Keystone Franklin, Inc. and Airshields, Inc. Mr. Kochanski started his career in public accounting at Price Waterhouse & Co.

Mr. Kochanski earned his Bachelor's degree and MBA from LaSalle University.

Joleen C. Turner - VP of Marketing and Business Development
Ms. Turner has over twenty years of international experience in strategic marketing, product development and product commercialization with high technology, professional service and life-science corporations. Since June 2006, she has been an independent consultant working with companies such as Boehringer Ingelheim, Pfizer, and Pepsico. She recently led a major marketing and packaging launch of a leading respiratory combination drug with revenues now exceeding US $1 billion. Previously Ms. Turner held the position of Director, Strategic Programs, for Aris Global where her strategic marketing initiatives contributed to the company's record growth and success in the safety, regulatory and medical information markets. Prior to her tenure at Aris Global, Ms. Turner served in various senior management positions at Platinum Technologies, Arthur D. Little Inc, and Recognition Equipment. Ms. Turner started her career as a software development engineer at Raytheon Data Systems.

Ms. Turner received a B.S. degree in Health Sciences from California State University, holds an MBA and Ph.D. degree in Business Administration and is a candidate for an M.S. degree in marketing from Alfred Whitehead College, Redlands University.

Gregory Collins, Ph.D. - Senior Scientist
R&D Program Manager with National Medical Care. BS in Chemical Engineering, Arizona State University; Ph.D. in Bioengineering, UC San Diego.

Nick Staub - Director Sales, US
VP, Development for Renal Ventures, developing joint venture dialysis clinics throughout the US. Territory Manager for Gambro US. BS in Business Administration, Menlo College.

Our Board of Directors

James S. Scibetta - Chairman of the Board - James Scibetta is the Chief Financial Officer of Pacira Pharmaceuticals. Prior to Pacira, Mr. Scibetta was Chief Financial Officer of Bioenvision, Inc. from December 2006 until its acquisition by Genzyme, Inc. in October 2007. From September 2001 to November 2006, Mr. Scibetta was Executive Vice President and CFO of Merrimack Pharmaceuticals, Inc., a biopharmaceutical company focused on discovery and development of novel therapies for autoimmune disease and cancer, and he was a member of the Board of Directors of Merrimack from April 1998 to March 2004. Mr. Scibetta formerly served as a senior investment banker at Shattuck Hammond Partners, LLC from 1997 to 2001 and PaineWebber Inc. from 1988 to 1997, providing capital acquisition, mergers and acquisitions, and strategic advisory services to healthcare companies. Mr. Scibetta is currently a member of the Board of Directors and Audit Committee Chairman of Labopharm, Inc., an international specialty pharmaceutical company focused on improving existing drugs by incorporating its proprietary, advanced controlled-release technologies. Mr. Scibetta holds a B.S. in Physics from Wake Forest University, and an M.B.A. in Finance from the University of Michigan. He completed executive education studies in the Harvard Business School Leadership & Strategy in Pharmaceuticals and Biotechnology program.

Eric A. Rose, MD - Valentine Mott/Johnson & Johnson Professor, Chairman of the Department of Surgery and Surgeon in Chief at the College of Physicians and Surgeons, Columbia Presbyterian Medical Center.

Lawrence J. Centella - President of Renal Patient Services, LLC. From 1997 to 1998, Executive Vice President and Chief Operating Officer of Gambro Healthcare, Inc.

Paul A. Mieyal - Dr. Mieyal is a Vice President and the Director of Life Sciences Investments of Wexford Capital LLC. Prior to that, he was Vice President in charge of health care investments for Wechsler & Co., Inc. a private investment firm and registered broker dealer. Dr. Mieyal serves as director of Nile Therapeutics, Inc., and several private companies. Dr. Mieyal received his Ph.D. in pharmacology from New York Medical College, a B.A. in chemistry and psychology from Case Western Reserve University, and is a Chartered Financial Analyst.

Arthur H. Amron - Mr. Amron is a partner of Wexford Capital and serves as its General Counsel. He actively participates in various private equity transactions, particularly in the bankruptcy and restructuring areas, and has served on the board committees of a number of public and private companies in which Wexford has held investments. Mr. Amron holds a JD from Harvard University, a B.A. in political theory from Colgate University, and is a member of the New York bar.

Scientific Advisory Board

John T. Daugirdas, MD - University of Illinois at Chicago School of Medicine Associate. Chief of Staff for research and Development, VA Chicago - Westside Medical Center. Co-author The Handbook of Dialysis.

Detlef Krieter, MD - Fellow at the University of Goettingen and University of Wuerzburg, Germany, and University of Montpellier and Renal Research and Training Institute, Montpellier, France; consultant at the Nephrology Center of Lower Saxony, Germany. Active researcher in the field of extracorporeal renal replacement therapies.

Leonard Stern, MD FACP - Medical Director at Columbia University Dialysis Center, and Assistant Professor of Clinical Medicine, Columbia University, College of Physician and Surgeons.